We found that acriflavine treatment of multiple CRC cell lines effectively inhibited TROP2‐driven proliferation (Figure 6A), tumourigenicity (Figures 6B and C and S7C and D) and migration (Figure S7A and B). This evidence concerns the gene TACSTD2 and colorectal carcinoma.